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1Human vitamin B12 absorption and metabolism are measured 
by accelerator mass spectrometry using specifically labeled 
14C-cobalamin.  




, Bruce A. 
Buchholz
§
, Joshua W. Miller¶, Ralph Green¶, Bruce D. Hammock||, John 
R. Roth** and Peter J. Anderson**,
††
*
Department of Nutrition, University of California, Davis, California, 95616-5270; 
†
Vitalea Science, Woodland, California, 
95776; ‡Department of Molecular Biosciences, University of California, Davis, California, 95616; §Center for Accelerator 
Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, California, 94551-9900; 
¶
Department of Medical 
Pathology and Laboratory Medicine, University of California, Sacramento, California, 95817, USA; 
||
Department of 
Entomology & Cancer Research Center, University of California, Davis, California, 95616, USA; **Section of Microbiology, 
University of California, Davis, California, 95616, USA.
††
To whom correspondence should be addressed. E-mail: pan@ucdavis.edu
Keywords:  Schilling test, cobalamin, metabolic engineering, ethanolamine, anemia, 
pernicious anemia, AMS
2There is need for an improved test of human ability to assimilate dietary vitamin B12.   
Assaying and understanding absorption and uptake of B12 is important because defects 
can lead to hematological and neurological complications.  Accelerator mass 
spectrometry (AMS) is uniquely suited for assessing absorption and kinetics of 14C-
labeled substances after oral ingestion because it is more sensitive than decay counting 
and can measure levels of carbon-14 (14C) in microliter volumes of biological samples, 
with negligible exposure of subjects to radioactivity. The test we describe employs 
amounts of B12 in the range of normal dietary intake.  The B12 used was quantitatively 
labeled with 14C at one particular atom of the DMB moiety by exploiting idiosyncrasies of 
Salmonella metabolism.   In order to grow aerobically on ethanolamine, S. enterica must 
be provided with either pre-formed B12 or two of its precursors: cobinamide and 
dimethylbenzimidazole (DMB).  When provided with 14C-DMB specifically labeled in the 
C2 position, cells produced 14C-B12 of high specific activity (2.1 GBq/mmol, 58 
mCi/mmol) and no detectable dilution of label from endogenous DMB synthesis.  In a 
human kinetic study, a physiological dose (1.5 mg, 2.2 KBq/59 nCi) of purified 14C-B12
was administered and showed plasma appearance and clearance curves consistent with 
the predicted behavior of the pure vitamin.  This method opens new avenues for study 
of B12 assimilation.
3Vitamin B12 (B12) is a compound of significant nutritional and clinical importance (1). The 
classical manifestations of B12 deficiency include pernicious anemia, a type of 
megaloblastic anemia, and neurological dysfunction (2).  The Schilling urinary excretion 
test (3, 4) indirectly measures B12 absorption and has been applied when B12
insufficiency is identified and malabsorption is the suspected cause.  The test involves 
ingestion of a physiological quantity of B12 labeled with gamma-emitting cobalt, followed 
by administration of a pharmacological parenteral flushing dose of unlabeled B12 to force 
urinary excretion of radioactivity, which is measured over a twenty-four hour period.  
The Schilling test is currently the only accepted method for assessing B12 absorption. 
Despite its utility, the method is semi-quantitative and has methodological and practical 
problems; it is now rarely prescribed, despite the prevalence of B12 malabsorption in 
older adults (2, 5).  We describe a new method that has potential to reinvigorate 
interest in diagnosis of the underlying causes of vitamin B12 deficiency.  The test has 
several advantages over the Schilling test --it poses a negligible radiation exposure to 
the subjects and medical workers and can be performed from a capillary-sized blood 
sample, without the requirement for a flushing dose of B12 or for collection of radioactive 
urine for an extended period.
The absorption test described uses carbon 14-labeled vitamin B12 (14C-B12) coupled to 
sensitive detection of the 14C-B12 by accelerator mass spectrometry (AMS).  AMS was 
originally developed for carbon dating in archaeological or earth science samples, 
however in the past decade or so its sensitivity has been exploited for tracing of 
biological systems (6).  In contrast to liquid scintillation counting, which records decay 
events of a radioisotope, AMS is a direct atom-counter that was developed for 
4quantifying long-lived isotopes such as 14C (half-life 5,370 yr).  It is a tandem isotope 
ratio mass spectrometer that provides the relative abundance of the 14C atom with 
respect to total carbon (14C/C) down to parts per quadrillion (1 in 1015)  (6-8).  Thus it is 
possible to quantify attomole (10-18 mol) amounts of 14C in a milligram-sized biological 
sample at high precision (typically < 2% imprecision).  The remarkable combination of 
sensitivity and precision of AMS allows quantitation of 14C-labeled B12 from small 
biological samples and reduces exposure of subjects to a negligible radiation risk.
The key to the success of the B12 absorption test we describe is the synthesis of 14C-B12
by an efficient, micro-scale method which produces 14C-B12 specifically labeled at the 
carbon 2 position of the dimethylbenzimidazole (DMB) moiety of B12.  This B12 is 
produced by Salmonella enterica, a bacterium that normally produces B12 de novo only 
under anaerobic conditions and uses it to support growth on ethanolamine.  Cells cannot 
grow aerobically on ethanolamine because they fail to synthesize two B12 precursors, 
cobinamide and DMB, but they retain ability to assemble B12 from these precursors 
supplied exogenously.  When isotopically labeled DMB is supplied, B12 is produced with 
no detectable isotope dilution.  The processes leading to the biosynthesis of 14C-B12 by 
S. enterica are shown in Figure 1.  The 14C-B12 synthesized by this method was used for 
quantitative AMS-based assay of human B12 absorption. 
 
5Results
Metabolic engineering of S. enterica for biosynthesis of 14C-labeled B12
The method used to produce labeled B12 relies on two idiosyncrasies of B12 metabolism 
in Salmonella enterica.  Under aerobic conditions on minimal medium with ethanolamine 
as sole carbon source, S. enterica produces neither cobinamide (the corrinoid precursor) 
nor DMB (the lower ligand of B12), but retains ability to assemble B12 when these 
precursors are provided exogenously. 
The 17-gene ethanolamine (eut) operon (9) of S. enterica is shown in Figure 2a.  
Induction of eut and the growth conditions pertinent to this work are shown in Figure 
2b.  Induction of the eut operon was monitored by assay of b-galactosidase produced by 
a lacZ gene inserted within a transcribed region of the eut operon that is distal to all 
genes of the operon.  The basal level of eut transcription produces 10 Miller units of b-
galactosidase activity from an operon fusion and increases about 50-fold when the 
operon is induced by the combination of B12 plus ethanolamine.  Surprisingly, the B12
precursor cobinamide can replace B12 as an inducer but does not permit growth on 
ethanolamine (Figure 2b).  This failure to produce B12 is due to lack of DMB since B12
production and growth on ethanolamine is restored if DMB is provided in addition to 
cobinamide.  Thus, during aerobic growth on ethanolamine, S. enterica fails to make 
both cobinamide and DMB, but can synthesize B12 if these precursors are provided.  The 
CobA, U, S, T, C and EutT enzymes, which catalyze conversion of cobinamide plus DMB 
to B12 are produced at levels sufficient to assemble B12 and permit aerobic cell growth on 
ethanolamine.    This provides a situation for efficient conversion of labeled precursors 
into B12 without label dilution.  The growth conditions used appear to avoid feedback 
6repression of B12 synthesis, presumably because B12 is sequestered and bound by the 
EutBC enzyme.
Synthesis and purification of 14C-labeled DMB and incorporation into B12
High specific activity 14C-labeled DMB was synthesized by condensation of 14C formic 
acid with dimethylphenylenediamine (10) (Figure 1).  The reaction product, [2-14C]-
dimethylbenzimidazole, was purified by HPLC to eliminate unwanted reaction products.  
When this labeled DMB and unlabeled cobinamide were provided to S. enterica, the cells 
produced B12 and grew aerobically on ethanolamine. 
Purification and mass spectral analysis of 14C-B12
Adenosylcobalamin was extracted from bacteria in the presence of cyanide so that 
highly stable cyanocobalamin (vitamin B12) would be formed.  These extracts were 
purified by HPLC and analyzed by two methods of mass spectrometry to establish 
chemical identity.  The 14C radiolabel co-eluted precisely with the single chromatographic 
peak of the vitamin B12 standard (Figure 3a).  The UV/visible absorption spectrum of the 
purified 14C-compound was consistent with that of the B12 standard spectrum (Figure 
3b).  The putative 14C-labeled cyanocobalamin (B12) was also analyzed by two forms of 
mass spectrometry; the MS/MS product spectra of the vitamin B12 standard, (M+H)+ at 
m/z 1355.8, and the 14C-labeled vitamin B12, (M+H)+ at m/z 1357.8, are shown in Figure 
4.  There is a 2 Da mass difference between the molecular ions of standard and the 14C-
labeled cobalamins; the fragmentation pattern confirms that this is due to a single 14C-
label on the 5,6-dimethylbenzimidazole moiety.  The molecular ion (M+H+) of the 
unlabeled B12 was compared to the 14C-labeled compound also by high resolution MS.  
7The measured values for both the unlabeled (m/z 1355.5741) and 14C-labeled cobalamin 
(m/z 1357.5787) agreed in molecular mass with the predicted values (m/z 1355.5752 
and m/z 1357.5782, respectively).  Based on the identified decomposition products of 
the MS/MS experiments, the accurate mass measurement data, and the HPLC data, we 
conclude that the product of the directed biosynthesis is ([2-14C]5,6-
dimethylbenzimidazole) cyanocobalamin.
Specific Activity of 14C-B12
The theoretical specific activity for a compound with 1 atom of 14C at 100% 
incorporation is 2.308 GBq/mmol.  Mass spectral analysis of the DMB isotopomers 
synthesized as described above indicated that 91% of the DMB product contained the 
14C label, thus the specific activity was 2.1 GBq/mmol (data not shown).  MS analysis of 
the 14C-B12 indicated that the DMB had been incorporated into the 14C-B12 without 
detectable dilution by endogenous DMB synthesis. The 14C-B12 therefore had 
approximately the same specific activity, 2.1 GBq/mmol. The total mass yield of vitamin 
B12 produced from the incubation was 25 µg (18.6 nmoles as cyanocobalamin). 
Human B12 absorption
The time course for the appearance and disappearance of 14C in plasma over seven days 
post-dose is presented in Figure 5.  Data are given as femtomoles of 14C-vitamin B12 per 
mL plasma.  After seven hours, the circulating 14C-B12 reached a peak, which 
corresponded to less than three percent of the administered dose of 14C-B12.  The 
amount of B12 detected at the peak would produce less than one disintegration per 
minute if assayed by scintillation counting, and thus would be unmeasurable by decay 
8counting.  There is a two to three hour delay in the appearance of the label in plasma, 
consistent with the time taken for gastric emptying and facilitated absorption in the 
ileum.  After the maximum level of 14C-B12 was achieved, the concentration of the label 
decreased at a single rate, with evidence for a small reappearance in plasma four days 
post-dose.  A radiochromatogram of cyanidated plasma, taken from the Cmax sample, 
revealed that the majority of the 14C co-migrated with cyanocobalamin on a reversed-
phase HPLC system (data not shown).
Figure 6 illustrates recovery of the label in urine and stool specimens seven days post-
dose.  The largest single concentration of label appeared in the twenty-four hour urine 
collection (6.8% of administered dose).  The apparent excretion of 6.8% of the B12 dose 
in the 24 hour urine does not agree with previously reported values of 0.10-0.41% 
urinary B12 excretion for normal subjects given radiocobalt B12 with no flushing dose of 
B12 (11).  However, a radiochromatogram of cyanidated urine indicates that only 
approximately 1.47% of the 14C urinary analytes was 14C-B12 (data not shown).  Thus the 
total 24 hour urine 14C-B12 is approximately 0.1% of the total 14C-B12 dose given, in 
agreement with previous measurements.  The chromatographic analysis of the urine 
showed that the bulk of the label is distributed among several peaks with mobility distinct 
from that of B12 or free DMB.   These may be breakdown products of B12 that were not 
detected for the cobalt labeled compound.  After seven days, a total of 15.8% of the oral 
dose was recovered in urine and feces.  Ninety-nine percent of the total quantified 
urinary and fecal output was accounted for seventy-two hours post-dose.
9Discussion
The absorption of B12 in humans is a complex process compared with absorption of other 
water-soluble vitamins, requiring a specific intestinal transport protein produced in the 
stomach (intrinsic factor) for active uptake.  This process is quickly saturated and doses 
greater than the current Recommended Dietary Allowance (2.4 mg/day US; 2.0 mg/day 
Europe) are passed unabsorbed into stool.  Therefore, sensitive absorption tests are 
necessary to assess absorption of B12 at normal dietary levels.  Recently a new, 
nonradioactive method for assessing vitamin B12 absorption has been reported (17).  The 
method seeks to correlate B12 absorption with an increase in holo-transcobalamin using 
ELISA.  While this method holds promise, in its current form it lacks the ability to deliver an 
unequivocal B12 absorption/malabsorption result and cannot convey quantitative or kinetic 
information.  The data described in the present study suggest that a more robust method 
for assaying B12 absorption and turnover can be developed that relies on use of AMS to 
detect physiological levels of suitably labeled B12 with high precision.  Production of 14C-B12
substrate is critical for this improved method.
B12 biosynthesis starts either from succinyl-CoA and glycine (the Shemin or C4 pathway) or, 
alternatively, from glutamyl-tRNA (the C5 pathway) (12).  These primary metabolites have 
manifold roles and are not solely committed to B12 biosynthesis; their use as a source of 
radiolabel for B12 would result in significant label dilution.  In the described method, a 
specific atom of B12 is labeled with 14C using a committed, late intermediate, DMB. 
Dimethylbenzimidazole is an ideal molecule for labeling B12 because it appears to have only 
a single metabolic fate: incorporation into the a-ligand of B12.  Fortuitously, it is both stable 
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and inexpensive to radiolabel by a one-step reaction from 14C-formic acid and 
dimethylphenylenediamine.  This precursor is efficiently introduced into B12 by cells of 
S. enterica because of several metabolic idiosyncrasies of this bacterium. S. enterica has a 
well characterized de novo biosynthetic pathway for B12 (13) that functions only in the 
absence of oxygen (14).  When grown aerobically on glucose with cobinamide, S. enterica
makes B12 using endogenously synthesized DMB (15), which would dilute the label of any 
added DMB.  However, when ethanolamine is the sole carbon source, aerobic S. enterica 
cells synthesize neither cobinamide nor DMB and both must be added to allow B12
production and growth (Figure 1). Thus, during growth of Salmonella on ethanolamine, 14C-
labeled dimethylbenzimidazole provided with cobinamide allows for efficient and specific 
labeling of B12.
The use of this labeled B12 and AMS to assay B12 absorption was demonstrated in a single, 
healthy, normal volunteer.  A single 1.5 mg dose of the 14C-B12 was administered orally and 
detected by AMS as it appeared in the bloodstream.  Normally, the release of B12 from 
intestinal mucosa cells into the portal vein occurs approximately two hours after the oral 
consumption of the vitamin, while release into systemic circulation takes an additional hour 
(16).  Consistent with this, the 14C from the labeled B12 appeared in the plasma of the 
human subject three hours post-dose.  A concentration peak of 5 – 6 fmol 14C-B12/ml was 
observed between five and twelve hours on either side of the Cmax, which occurred at seven 
hours (Figure 5).  This time window would make it possible to assess B12 absorption from a 
single capillary blood sample.  The current Schilling urinary excretion test, which has been 
the standard method of assessing B12 absorption since its introduction in 1953, is now 
rarely prescribed as it requires administration of radiocobalt B12, followed by an 
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intramuscular flushing dose and twenty-four hour total urine collection.  By this method, 
patients with normal B12 absorption excrete eight to forty percent of the labeled B12 in the 
urine, compared with patients who have malabsorption, from whom there is little or no 
recovery of labeled B12 from urine (4). By contrast, the method we describe makes it 
possible to follow the fate of the vitamin, at near ambient levels of radiation exposure, 
using microliter-sized blood specimens and without a flushing dose.  Relatively little of the 
dose was recovered in either urine or stool; eighty four percent of the administered dose 
was retained in body tissues after seven days.  This observation is consistent with the very 
slow body elimination of B12 (0.1% loss per day after initial excretion of the unabsorbed 
dose) due to efficient enterohepatic recycling.  The 6.8% loss in the 24-hour urine was 
unexpected in the absence of a parenteral flushing dose, based on previous experiments 
carried out using radiocobalt B12.  Examination of the chromatographic behavior of 14C 
labeled compounds in the urine revealed that the predominant urinary products were not 
vitamin B12.  The accumulation of 14C-B12 degradation products in the urine may be due to 
acid hydrolysis of some of the 14C-B12 dose in the stomach or due to bacterial degradation 
in the gut with consequent release of DMB.  Absorption of free DMB and its metabolism, 
such as through hepatic conjugation to glucuronide, may result in urinary excretion of the 
product.  However, further analysis is necessary to determine the exact nature of the 
products detected in the urine.  
In summary, we describe the biosynthesis of 14C-labeled B12 and human absorption kinetics 
using near-ambient levels of radiation that pose little or no risk from exposure.  The 
sensitivity of AMS reduces the needed sample size to only tens of microliters of blood and 
minimizes exposure to radiation.  We believe that combined use of 14C-labeled B12 and AMS 
detection has the potential to be a powerful clinical diagnostic tool and an improved 
12
method for studying the underlying causes of B12 uptake disorders, including the 
development of a sensitive and quantitative test for B12 absorption in humans. 
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Methods
Synthesis and purification of 14C-dimethylbenzimidazole
Radiolabeled DMB was synthesized using a procedure modified from that of Phillips (10). 
Into a 10 mL boiling flask containing 500μL of sodium phosphate buffer (pH=7.4, 100 
mM) was added 14C-formic acid (1 mCi; 0.0182mmoles, 1.85-2.22 GBq/mmol; Moravek 
Biochemicals, Brea, CA).  The material was dried under reduced pressure and the solids 
were dissolved in 1 mL of 4M HCl. To initiate the reaction, 15.15 mg (111 mmoles) of o-
dimethylphenylenediamine was added and the contents taken to a vigorous boil using a 
reflux system with the condenser maintained at -10°C using a recirculating chiller.  After 
2 hours of heating the reaction solution was neutralized by dropwise addition of 
concentrated ammonium hydroxide to approximately pH 7.  The reaction product was 
then loaded onto a solid-phase extraction cartridge (1 g Bond Elut C18, Varian), which 
had been primed with 3 mL of methanol and 3 mL deionized water.  The column was 
washed with 2 column volumes of deionized water and the bound 14C-DMB eluted with 
methanol (3 mL). 
The solvent was removed under streaming nitrogen and the product dissolved in 0.5 mL 
of absolute ethanol.  The product was then purified by multiple injections onto an 
isocratic reverse-phase HPLC using an Agilent 1100 chromatograph fitted with an Alltech 
Adsorbosphere HS C18 column (150mm x 4.6mm).  The isocratic mobile phase, 
34:33:33 water:methanol:acetonitrile, was pumped at a flow rate of 0.80 mL/min; the 
absorbance of the outflow was monitored at 284 nm.  The peaks, which had similar 
retention and spectral characteristics to a purchased DMB standard (Sigma), were 
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pooled and evaporated to dryness under reduced pressure, dissolved in absolute ethanol 
and stored at –70 oC.  Radioactivity was determined by liquid scintillation counting. 
Microorganism cultivation
The strain used for reporting b-galactosidase activity was TT10674, genotype 
eut38::mudA.  The strain used for 14C-B12 biosynthesis was Salmonella enterica (serovar
Typhimurium) strain TT24733, genotype cbiD24::MudJ.  The labeling medium consisted 
of no carbon E (NCE) medium (17) supplemented with 40mM ethanolamine, 250nM 
dicyanocobinamide and 500nM 14C-DMB synthesized as described above. Approximately 
130 mL of labeling medium was added to a sterile 500mL conical flask.  The medium 
(130mL in a 500ml flask) was inoculated by a 100 dilution of a S. enterica culture grown 
in NCE medium supplemented with 20mM glycerol.  Cultures were incubated in the dark 
for 24 hours at 30o C with shaking at 250 rpm.
Extraction and purification of 14C-cyanocobalamin from cells
Bacterial cells were pelleted by centrifugation for 20 minutes at 6,000 x g.  Supernatants 
were removed and cell pellets washed three times with NCE medium (17).  The pellets 
were resuspended in 5 mL methanol and 500 mL of 50 mg/mL sodium cyanide, vortex 
mixed, then placed in a 60°C water bath for 12 hours with intermittent vortex mixing.  
The samples were then centrifuged at 20,000 x g for one hour.  The supernatants were 
removed from the pellet and evaporated to dryness.  Dried samples were resuspended 
in water and filtered (0.22µm) to remove any insoluble material.  A first step in 
purification of the 14C-B12 was performed by extraction on C18:0 solid phase extraction 
cartridges (5g bond Elut C18, Varian).  The corrinoids were eluted with 50:50 
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water:methanol and the solvent evaporated to dryness.  Purification to homogeneity 
was carried out by HPLC on an Agilent series 1100 HPLC equipped with a diode array 
detector and fitted with an Agilent Zorbax Eclipse XDB C18 (3.5μm) column (150mm x 
3.0mm).  Solvent A was 90/10 water/methanol and solvent B was methanol with initial 
conditions of 82/18 A/B.  At 12 minutes a linear gradient was started which reached 
25/75 A/B after 16 min.  The flow rate was held constant at 0.360 mL/min.  Extracts 
were run in multiple injections and the peak corresponding to 14C-cyanocobalamin was 
collected and pooled for each run.  The solvent was evaporated to dryness and samples 
resuspended in water for storage at -70ºC. 
Mass Spectrometry   
High Resolution Mass spectrometry-Accurate Mass Measurement
Exact mass measurement experiments were performed, in positive mode, on Micromass 
LCT orthogonal acceleration-Time-of-Flight mass spectrometer (Waters-Micromass, 
Manchester, UK). The cone gas and desolvation gas were set to 50 and 650 L/hour, 
respectively.  Resolution was 8000, measured at 803 Th mass, based on the definition of 
FWHM (full width at half maximum).  Sample source conditions were as follows: 
capillary voltage 3250 V, sample cone voltage 30 V, extraction cone voltage 6 V, source 
temperature 100 °C and desolvation temperature 250 °C. Transfer optics settings were 
as follows: rf lens 250 V, rf dc offset-1 4.0 V, rf dc offset-2 6.0 V, aperture 2.0 V, 
acceleration 200.0 V, focus 1.0 V and steering -0.3 V.  Analyzer settings were as follows: 
MCP (multi channel plate) detector 2430 V, ion energy 32.0 V, tube lens 4.0 V, grid-2
20.0 V, TOF flight tube 4599 V and reflectron 1713 V.  The pusher cycle time was 50 μs, 
data files were acquired in continuum mode and spectra were stored from m/z 100 to 
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1600 with a 1.1 second scanning cycle consisting of a 1.0 second scan and a 0.1 second 
inter-scan time. Typically 20-30 individual spectra were summarized. TOF Calibration: 
Lteff (effective length of the flight tube) value was set to 1122.7250 in positive mode 
using molecular ions of leucine-enkephalin (L9133, Sigma, MO, USA) at 556.2771 Th.  
System calibration was performed using poly-D-L-alanine (P9003, Sigma, MO, USA) 
which was also used as an internal standard for accurate mass measurement. To obtain 
accurate masses the following procedure was performed: Savitsky-Golay smoothing 
using ± 4 channel window, repeated twice and centering, using the center value at the 
50% height of the peak. Samples were introduced to the mass spectrometer via direct 
flow injection using Waters Alliance 2795 (Bedford, MA, USA) HPLC system was used for 
solvent delivery at the flow rate of 250 µL/min, mobile phase CH3CN/H2O (1/1) was 
used. MassLynx 4.0 sp 3 software (Waters-Micromass, Manchester, UK) was used for 
instrument control, data acquisition and data evaluation. 
MS/MS experiments
Positive ion MS/MS experiments were performed in product mode on a Quattro Premier 
(Waters-Micromass, Manchester, UK) triple quadrapole mass spectrometer with a 
configuration of QTQ equipped with an interface sprayer (API interface). The instrument 
was operated with the following instrumental conditions: source temperature, 120 °C; 
desolvation temperature, 200 °C; capillary voltage, 3.1 kV; cone voltage, 50 V; 
extraction cone, 5 V, RF lens 0.5 V. Drying gas as well as cone gas was nitrogen, the 
cone gas flow was set to 50 L/h and the desolvation gas flow to 700 L/h. Quadrapole-1 
parameters were as follows: Low mass (LM) resolution 14.0, high mass (HM) resolution 
14.0, ion energy 0.4-0.6 V, entrance 7 V, exit 16 V; Quadrapole-2 parameters were LM 
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resolution 15.5, HM resolution 15.5 V, ion energy 2.0- 2.5 V. Multipliers were set at 550 
V.  Collision gas was Argon (99.9999%, Airgas, Inc., Radnor, PA, USA) with a pressure 
of 3.6-4.6×10-3 mbar in the collision cell. MS/MS experiments were performed at 
collision energy of 50-70 eV (in the case of single charged ions) and 30-40 eV energy (in 
the case of double charged ions). MS/MS data were acquired in continuous mode, 
scanning speed was in all cases 0.025 sec/decade with 0.1 second inter-scan time, 
sampling density was set at 16/Da. Infusion experiments were performed on an integral 
syringe pump controlled from MassLynx, with a flow rate of 20  µL/ minute, directly 
connected to the interface. Data acquisition, instrument control was performed using 
MassLynx 4.0 sp 3 software (Waters-Micromass, Manchester, UK).
Subjects and Human Experimental Design
The subject was a healthy male aged 40 years with a body mass index (BMI) of 27.5.  
The subject began complete fecal and urine collection 24 h in advance of the C14-B12 
dose and continued complete 24 h collections continued until Day 7.  On the day of dose 
administration, the subject was fitted with an intravenous catheter in a forearm vein. 
Blood was drawn into 7 mL tubes containing EDTA. A baseline blood sample was drawn 
(7 AM) and the C14-B12 dose consumed that corresponded to 2.2 KBq of radioactivity 
(1.5 mg) was administered in 50 mL of drinking water in a paper cup.  The volunteer 
was allowed to have water ad libitum thereafter, with a light meal taken 2 hr postdose.  
Blood samples (5mL) were drawn at frequent intervals for the first 15 hr post-dose and 
daily thereafter. Other meals were controlled for time and content on the dose 
administration day.   The study was conducted in accordance with the ethical guidelines 
of the 1975 Declaration of Helsinki and approved by the Institutional Review Boards at 
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UC Davis and Lawrence Livermore National Laboratory.  Informed consent was obtained 
from the subject.
AMS analysis
Aliquots of plasma (30mL), urine (80mL) and a stool slurry (80mL) were dried, combusted to 
CO2, and reduced to filamentous carbon using previously described procedures (18),(19).    
No other processing preceded the graphitization step, thus quantitative recovery was 
ensured.  The 14C measurements were performed at the Center for Accelerator Mass
Spectrometry at Lawrence Livermore National Laboratory (20). Measurements were 
conducted to < 3% instrument imprecision and, in general, signal acquisition was complete 
to the desired statistical precision in 3-5 min per sample.  The radiation exposure of the 
subject, due to the 14C-B12 dose, was equivalent to or less than exposure due to 16 hours of 
intercontinental plane flight (7, 21).
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Figure Legends
Figure 1: Synthesis of cofactor B12 from cobinamide and 14C-dimethylbenzimidazole 
during growth on ethanolamine.  S. enterica enzymes CobTUSC and EutT catalyze the 
synthesis of adenosylcobalamin (22, 23).  Growth on ethanolamine proceeds by 
ethanolamine ammonia lyase EutBC which requires adenosylcobalamin to catalyze the 
formation of acetaldehyde from ethanolamine.
Figure 2:  (a) Organization of the 17 gene eut operon.  Genes are transcribed from left 
to right from the primary promoter P1.  P2 is  a weak constitutive promoter.  (b) 
Induction of the eut operon in the presence of ethanolamine and glycerol is compared to 
growth on ethanolamine as sole carbon source.
Figure 3:  (a) Precise coelution of the 14C radiolabel with B12.  (b) Comparison of 
standard vitamin B12 with that of the putative 14C-B12 extract.
Figure 4:  MS/MS spectra in product mode showing the decomposition products of the 
molecular ions (M+H)+ of B12 and 14C-B12 vitamin.
Figure 5: Accelerator mass spectrometry detection of 14C in human plasma.  Units are 
expressed as femtomolar 14C-B12.  Measurements were performed on 30 ml of plasma, 
the entire sample set consumed less than 1 mL of whole blood.
Figure 6:  Recovery of 14C in  urine and fecal specimens, and cumulative recovery of 14C.  
After seven days, 15.9% of the dose was recovered in the urine and stool.
